Abstract
Some data suggest that adjuvant therapy after surgical resection for pancreatic cancer may improve long-term survival, but it is not used routinely because evidence from randomized studies is inconclusive. The European Study Group for Pancreatic Cancer randomly assigned 289 patients who had undergone complete macroscopic resection of histologically proven pancreatic ductal adenocarcinoma to receive postoperative chemoradiotherapy alone, chemotherapy alone, combination chemoradiotherapy and chemotherapy, or neither treatment (observation). Clinical features and characteristics of the tumors were similar among groups. After a median follow-up of 47 months, …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
